The Catecholamine Release-Inhibitory “Catestatin” Fragment of Chromogranin A: Naturally Occurring Human Variants with Different Potencies for Multiple Chromaffin Cell Nicotinic Cholinergic Responses

The catestatin fragment of chromogranin A is an endogenous inhibitor of nicotinic cholinergic transmission, functioning in negative feedback control of catecholamine secretion. We explored naturally occurring polymorphisms in the amino acid sequence of catestatin. Three human variants were identified: Gly364Ser, Pro370Leu, and Arg374Gln. Variants were tested for ability to inhibit four nicotinic processes. The rank order of potency for inhibition of catecholamine secretion was Pro370Leu > wild type > Gly364Ser > Arg374Gln. Decrease in potency was paralleled by decline in Hill slope, suggesting that negative cooperativity at ascending dose might underlie loss of potency. Several lines of evidence indicated that each variant acted as a nicotinic antagonist: potency to inhibit secretion paralleled inhibition of agonist-triggered 22Na+ uptake (r = 0.986); variants inhibited secretion with similar potency when triggered by several nicotinic agonists, though not by agents using other secretory pathways or bypassing the nicotinic receptor; and blockade of secretion was noncompetitive with agonist. Variants also inhibited desensitization of secretion after prior agonist exposure and stimulation of secretory protein biosynthesis by agonist. Rank order of variant inhibitory potency for all four nicotinic processes was identical (Pro370Leu > wild type > Gly364Ser > Arg374Gln), suggesting mediation by similar combinations of receptor α/β subunits and that crucial catestatin residues are likely to be identical across the four processes. When catestatin variants were mixed in likely heterozygotic (1:1 M ratio) combinations, the inhibitory curve was left-shifted onto that of the more potent variant in the combination, suggesting phenotypic dominance. The results have quantitative implications for interindividual variations in human nicotinic signaling.

[1]  D. Falconer,et al.  Introduction to Quantitative Genetics. , 1962 .

[2]  D. O'Connor,et al.  A crucial role for the mitogen-activated protein kinase pathway in nicotinic cholinergic signaling to secretory protein transcription in pheochromocytoma cells. , 1998, Molecular pharmacology.

[3]  H Wu,et al.  Formation of the Catecholamine Release-inhibitory Peptide Catestatin from Chromogranin A , 2000, The Journal of Biological Chemistry.

[4]  D. O'Connor,et al.  Modulatory Mechanism of the Endogenous Peptide Catestatin on Neuronal Nicotinic Acetylcholine Receptors and Exocytosis , 2002, The Journal of Neuroscience.

[5]  D. O'Connor,et al.  Chromaffin cell catecholamine secretion: bisindolylmaleimide compounds exhibit novel and potent antagonist effects at the nicotinic cholinergic receptor in pheochromocytoma cells. , 2002, Molecular pharmacology.

[6]  D. O'Connor,et al.  Peptidergic activation of transcription and secretion in chromaffin cells. Cis and trans signaling determinants of pituitary adenylyl cyclase-activating polypeptide (PACAP). , 1998, The Journal of clinical investigation.

[7]  V. Dequattro,et al.  The sympathetic nervous system: the muse of primary hypertension , 2002, Journal of Human Hypertension.

[8]  D. O'Connor,et al.  Catecholamine storage vesicle protein expression in genetic hypertension. , 1999, Blood pressure.

[9]  D. O'Connor,et al.  Catecholamine Secretory Vesicle Stimulus-Transcription Coupling in Vivo , 2003, Journal of Biological Chemistry.

[10]  D T O'Connor,et al.  Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity. , 2000, Molecular endocrinology.

[11]  A. D. Smith,et al.  [39] Adrenal chromaffin granules: Isolation and disassembly , 1974 .

[12]  L. Greene,et al.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. O'Connor,et al.  Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells. , 2003, Biochemistry.

[14]  R. Fischer‐Colbrie,et al.  The chromogranins A and B: The first 25 years and future perspectives , 1992, Neuroscience.

[15]  J. Daly,et al.  Epibatidine, a potent analgetic and nicotinic agonist. , 1994, Molecular pharmacology.

[16]  B. Kennedy,et al.  Chromogranin A in human hypertension. Influence of heredity. , 1995, Hypertension.

[17]  D. O'Connor,et al.  Time-dependent effects of the neuropeptide PACAP on catecholamine secretion : stimulation and desensitization. , 1999, Hypertension.

[18]  D. O'Connor,et al.  Structure and function of the chromogranin A gene. Clues to evolution and tissue-specific expression. , 1991, The Journal of biological chemistry.

[19]  D. O'Connor,et al.  Stimulus-transcription Coupling in Pheochromocytoma Cells , 1996, The Journal of Biological Chemistry.

[20]  A. D. Smith,et al.  Adrenal chromaffin granules: isolation and disassembly. , 1974, Methods in enzymology.

[21]  D. O'Connor,et al.  Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A , 2004, Regulatory Peptides.

[22]  A. Garcı́a,et al.  Unmasking the functions of the chromaffin cell alpha7 nicotinic receptor by using short pulses of acetylcholine and selective blockers. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  V. Mutt,et al.  Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion , 1986, Nature.

[24]  D. O'Connor,et al.  Is physiologic sympathoadrenal catecholamine release exocytotic in humans? , 1990, Circulation.

[25]  G. Sperk,et al.  An Increased Pool of Secretory Hormones and Peptides in Adrenal Medulla of Stroke‐Prone Spontaneously Hypertensive Rats , 1989, Hypertension.

[26]  K. Helle,et al.  Vasostatins, Comprising the N‐terminal Domain of Chromogranin A, Suppress Tension in Isolated Human Blood Vessel Segments , 1993, Journal of neuroendocrinology.

[27]  D. O'Connor,et al.  Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. , 1997, The Journal of clinical investigation.

[28]  Douglas W. Smith,et al.  Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. , 2004, American journal of human genetics.

[29]  D. O'Connor,et al.  Human chromogranin A. Purification and characterization from catecholamine storage vesicles of human pheochromocytoma. , 1984, Hypertension.

[30]  Igor Tsigelny,et al.  Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a β-strand/loop/β-strand structure secured by hydrophobic interactions and predictive of activity , 1998, Regulatory Peptides.

[31]  D. O'Connor,et al.  Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion. , 1996, Hypertension.

[32]  D. O'Connor,et al.  Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary hypertension. , 1993, Hypertension.

[33]  D. O'Connor,et al.  Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. , 2002, Journal of hypertension.

[34]  S. Mahata,et al.  Desensitization of Catecholamine Release , 1999, The Journal of Biological Chemistry.

[35]  D. O'Connor,et al.  Secretin Activation of Chromogranin A Gene Transcription , 2003, Journal of Biological Chemistry.

[36]  D. O'Connor,et al.  Stimulus coupling to transcription versus secretion in pheochromocytoma cells. Convergent and divergent signal transduction pathways and the crucial roles for route of cytosolic calcium entry and protein kinase C. , 1997, The Journal of clinical investigation.

[37]  Jiangbei Cao,et al.  Antidepressant-like effect of agmatine and its possible mechanism. , 2003, European journal of pharmacology.

[38]  B. Conti-Tronconi,et al.  Identification of a brain acetylcholine receptor alpha subunit able to bind alpha-bungarotoxin. , 1990, The Journal of biological chemistry.

[39]  D. Seals,et al.  The ‘adrenaline hypothesis’ of hypertension revisited: evidence for adrenaline release from the heart of patients with essential hypertension , 2000, Journal of hypertension.

[40]  A. Tischler,et al.  Animal models of pheochromocytoma. , 2004, Histology and histopathology.